COSOPT OPHTHALMIC SOLUTION

Country: Singapura

Bahasa: Inggeris

Sumber: HSA (Health Sciences Authority)

Bahan aktif:

DORZOLAMIDE HCl; TIMOLOL MALEATE

Boleh didapati daripada:

SANTEN PHARMACEUTICAL ASIA PTE. LTD.

Kod ATC:

S01ED51

Dos:

2.00%

Borang farmaseutikal:

SOLUTION

Komposisi:

DORZOLAMIDE HCl 2%; TIMOLOL MALEATE 0.5%

Laluan pentadbiran:

OPHTHALMIC

Jenis preskripsi:

Prescription Only

Dikeluarkan oleh:

Santen Pharmaceutical Co., Ltd. Noto Plant

Status kebenaran:

ACTIVE

Tarikh kebenaran:

2001-08-22

Risalah maklumat

PACKAGE INSERT
Sterile Ophthalmic Solution
(dorzolamide hydrochloride and timolol maleate ophthalmic solution)
I. THERAPEUTIC CLASS
COSOPT
®
Ophthalmic Solution (dorzolamide hydrochloride and timolol maleate) is
the first combination
of a topical carbonic anhydrase inhibitor and a topical
beta-adrenergic receptor blocking agent.
II. CLINICAL PHARMACOLOGY
IIa. Mechanism of Action
COSOPT is comprised of two components: dorzolamide hydrochloride and
timolol maleate. Each of
these two components decreases elevated intraocular pressure by
reducing aqueous humor secretion,
but does so by a different mechanism of action.
Dorzolamide hydrochloride is a potent inhibitor of human carbonic
anhydrase II. Inhibition of carbonic
anhydrase in the ciliary processes of the eye decreases aqueous humor
secretion, presumably by
slowing the formation of bicarbonate ions with subsequent reduction in
sodium and fluid transport.
Timolol maleate is a nonselective beta-adrenergic receptor blocking
agent that does not have significant
intrinsic sympathomimetic, direct myocardial depressant, or local
anesthetic (membrane-stabilizing)
activity. The combined effect of these two agents results in
additional intraocular pressure reduction
compared to either component administered alone.
Following topical administration, COSOPT reduces elevated intraocular
pressure, whether or not
associated with glaucoma. Elevated intraocular pressure is a major
risk factor in the pathogenesis of
optic nerve damage and glaucomatous visual field loss. The higher the
level of intraocular pressure, the
greater the likelihood of glaucomatous visual field loss and optic
nerve damage. COSOPT reduces
intraocular pressure without the common side effects of miotics such
as night blindness,
accommodative spasm and pupillary constriction.
IIb. Pharmacokinetics / Pharmacodynamics
Dorzolamide Hydrochloride
Unlike oral carbonic anhydrase inhibitors, topical administration of
dorzolamide hydrochloride allows for
the drug to exert its effects directly in the eye at substantia

Ciri produk

PACKAGE INSERT
Sterile Ophthalmic Solution
(dorzolamide hydrochloride and timolol maleate ophthalmic solution)
I. THERAPEUTIC CLASS
COSOPT
®
Ophthalmic Solution (dorzolamide hydrochloride and timolol maleate) is
the first combination
of a topical carbonic anhydrase inhibitor and a topical
beta-adrenergic receptor blocking agent.
II. CLINICAL PHARMACOLOGY
IIa. Mechanism of Action
COSOPT is comprised of two components: dorzolamide hydrochloride and
timolol maleate. Each of
these two components decreases elevated intraocular pressure by
reducing aqueous humor secretion,
but does so by a different mechanism of action.
Dorzolamide hydrochloride is a potent inhibitor of human carbonic
anhydrase II. Inhibition of carbonic
anhydrase in the ciliary processes of the eye decreases aqueous humor
secretion, presumably by
slowing the formation of bicarbonate ions with subsequent reduction in
sodium and fluid transport.
Timolol maleate is a nonselective beta-adrenergic receptor blocking
agent that does not have significant
intrinsic sympathomimetic, direct myocardial depressant, or local
anesthetic (membrane-stabilizing)
activity. The combined effect of these two agents results in
additional intraocular pressure reduction
compared to either component administered alone.
Following topical administration, COSOPT reduces elevated intraocular
pressure, whether or not
associated with glaucoma. Elevated intraocular pressure is a major
risk factor in the pathogenesis of
optic nerve damage and glaucomatous visual field loss. The higher the
level of intraocular pressure, the
greater the likelihood of glaucomatous visual field loss and optic
nerve damage. COSOPT reduces
intraocular pressure without the common side effects of miotics such
as night blindness,
accommodative spasm and pupillary constriction.
IIb. Pharmacokinetics / Pharmacodynamics
Dorzolamide Hydrochloride
Unlike oral carbonic anhydrase inhibitors, topical administration of
dorzolamide hydrochloride allows for
the drug to exert its effects directly in the eye at substantia